Category: iRhythm Technologies Inc.
iRhythm Technologies, which includes St. Jude Medical among its backers, lands a $16 million Series D round for its Zio wearable heart monitor.
iRhythm Technologies said it closed a $16 million Series D round for its Zio wearable heart monitor, saying it plans to use the proceeds to further its commercial footprint and research & development efforts.
Led by Norwest Venture Partners, which added partner Casper de Clercq to iRhythm's board, the latest financing including contributions from existing backers New Leaf Ventures, Synergy Life Science Partners and Kaiser Permanente Ventures.
Edwards Lifesciences is on track for mid-teens sales growth for its Sapien heart valve, according to a survey of 30 cardiologists by Leerink Swann analysts.
Edwards Lifesciences (NYSE:EW) is on track for solid growth in the transcatheter aortic valve implant market, according to a survey of cardiologists conducted by Leerink Swann analysts.
Medical device company Mako Surgical readies a public offering of more than 3 million shares worth more than $40 milion to help commercialize its Rio surgical robot.
Mako Surgical (NSDQ:MAKO) said it's planning to sell some 3 million shares of its own stock in an offering worth about $40 million.*
Barclays weighs in on the TAVI trials, Medtronic touts pacing as an option for patients prone to fainting, iRhythm touts study results for Zio Patch cardiac rhythm monitoring and more from this week's American College of Cardiology conference.
Barclays weighs in on TAVI results for Edwards Lifesciences
iRhythm Technologies raises another $15 million, including funds from lead equity round investor St. Jude Medical.
St. Jude Medical’s (NYSE:STJ) partnership with a California-based arrhythmia-diagnostic company is going well enough that it recently poured more money into that startup.